Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens

被引：1
|
作者：
Serafin, Andrea [1 ]
Cellini, Alessandro [1 ]
Cavarretta, Chiara Adele [1 ]
Ruocco, Valeria [1 ]
Angotzi, Francesco [1 ]
Zatta, Ivan [1 ]
Frezzato, Federica [1 ]
Bonaldi, Laura [2 ]
Martines, Annalisa [2 ]
Pravato, Stefano [1 ]
Piazza, Francesco [1 ]
Trentin, Livio [1 ]
Visentin, Andrea [1 ]
机构：
[1] Univ Padua, Dept Med, Hematol Unit, Via Nicolo Giustiniani 2, I-35128 Padua, PD, Italy
[2] Veneto Inst Oncol, Immunol & Mol Oncol Unit, IOV IRCCS, Padua, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 01期
关键词：
CK; high CK; MRD; venetoclax; CLL;
D O I：
10.1111/bjh.19517
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax-based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA-CLL13), specifically focus on this topic while real-word evidence is missing. In our real-life retrospective study conducted on 61 patients with CLL and treated with venetoclax-based regimens in any therapeutic line, we documented a remarkable lower progression-free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.
引用
收藏
页码：189 / 193
页数：5
相关论文
共 50 条
  • [41] Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcome
    Castryck, H
    Van den Driessche, M
    Hagemeijer, A
    Stul, M
    Wynendaele, W
    Vandenberghe, P
    Moerman, J
    CLINICAL AND LABORATORY HAEMATOLOGY, 2006, 28 (02): : 138 - 140
  • [42] Indirect treatment comparison analysis of venetoclax plus obinutuzumab with standard front-line regimens for chronic lymphocytic leukaemia
    Bastus, N. Coll
    Davids, M. S.
    Huntington, S. F.
    Moreno, C.
    Follows, G.
    Cuneo, A.
    Humphrey, K.
    Schary, W.
    Sail, K.
    Song, Y.
    Gao, Z.
    Tang, Z.
    Pena, G.
    Foa, R.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 219 - 220
  • [43] PROGNOSTIC ROLE OF KARYOTYPE IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH 13Q DELETION
    Martines, A.
    Visentin, A.
    Grassi, A.
    Filippi, B.
    Nalio, S.
    Macri, N.
    Facco, M.
    Amadori, A.
    Trentin, L.
    Bonaldi, L.
    HAEMATOLOGICA, 2018, 103 : S77 - S77
  • [44] COVID-19 among fit patients with CLL treated with venetoclax-based combinations
    Moritz Fürstenau
    Petra Langerbeins
    Nisha De Silva
    Anna Maria Fink
    Sandra Robrecht
    Julia von Tresckow
    Florian Simon
    Karin Hohloch
    Jolanda Droogendijk
    Marjolein van der Klift
    Ellen van der Spek
    Thomas Illmer
    Björn Schöttker
    Kirsten Fischer
    Clemens M. Wendtner
    Eugen Tausch
    Stephan Stilgenbauer
    Carsten U. Niemann
    Michael Gregor
    Arnon P. Kater
    Michael Hallek
    Barbara Eichhorst
    Leukemia, 2020, 34 : 2225 - 2229
  • [45] COVID-19 among fit patients with CLL treated with venetoclax-based combinations
    Fuerstenau, Moritz
    Langerbeins, Petra
    De Silva, Nisha
    Fink, Anna Maria
    Robrecht, Sandra
    von Tresckow, Julia
    Simon, Florian
    Hohloch, Karin
    Droogendijk, Jolanda
    van der Klift, Marjolein
    van der Spek, Ellen
    Illmer, Thomas
    Schoettker, Bjoern
    Fischer, Kirsten
    Wendtner, Clemens M.
    Tausch, Eugen
    Stilgenbauer, Stephan
    Niemann, Carsten U.
    Gregor, Michael
    Kater, Arnon P.
    Hallek, Michael
    Eichhorst, Barbara
    LEUKEMIA, 2020, 34 (08) : 2225 - 2229
  • [46] Spontaneous apoptosis in chronic lymphocytic leukaemia patients with adverse prognostic factors
    Kravic, T
    Boskovic, D
    Bumbasirevic, V
    Djuricic, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 199 - 199
  • [47] How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia
    Deodato, Marina
    Frustaci, Anna Maria
    Sportoletti, Paolo
    Laurenti, Luca
    Murru, Roberta
    Visentin, Andrea
    Reda, Gianluigi
    Mauro, Francesca Romana
    Quaresmini, Giulia
    Vanazzi, Anna
    Vitale, Candida
    Orsucci, Lorella
    Massaia, Massimo
    Sanna, Alessandro
    Motta, Marina
    Ibatici, Adalberto
    Ferrarini, Isacco
    Borella, Chiara
    Varettoni, Marzia
    Tani, Monica
    Marinoni, Sara
    Ferrario, Andrea
    Zamprogna, Giulia
    Montillo, Marco
    Tedeschi, Alessandra
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1985 - 1988
  • [48] The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype
    Strati, Paolo
    Takahashi, Koichi
    Wang, Feng
    Tambaro, Francesco Paolo
    Keating, Michael
    Ferrajoli, Alessandra
    Estrov, Zeev
    Thompson, Phil
    Jain, Nitin
    Bose, Prithviraj
    Futreal, Andrew
    Wierda, William
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S212 - S213
  • [49] Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients
    Wei, Shuning
    Gu, Runxia
    Song, Yang
    Yan, Zhangsong
    Hu, Yimin
    Lin, Dong
    Liu, Kaiqi
    Zhou, Chunlin
    Zhang, Guangji
    Wang, Ying
    Wang, Jianxiang
    Mi, Yingchang
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (05) : 772 - 776
  • [50] Reply to Smolej: The prognostic role of CLLU1 in chronic lymphocytic leukaemia
    Buhl, Anne Mette
    Jurlander, Jesper
    Geisler, Christian
    Leffers, Henrik
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (02) : 178 - 178
12345